Claim 1: an Antibody or Antigen binding fragment thereof, characterized in that it comprises a variable region of heavy chain (VH) and a Humanized light chain variable region (VL) Humanized； where the VH comprises an Amino Acid Sequence with the formula: hfw1 HC Hfw2 DR1 - - - - - hcdr2 hfw3 hcdr3 hfw4, where hfw1 is SEQ ID no. 6 or SEQ ID no. 7, hcdr1 is SEQ ID No. 8Hfw2 is SEQ ID no. 9, hcdr2 is SEQ ID no. 14, SEQ ID no. 15 or SEQ ID no. 16, hfw3 is SEQ ID no. 17, hcdr3 is SEQ ID no. 25, SEQ ID no. 26, or SEQ ID no. 27, and hfw4 is SEQ ID no. 28； where VL comprises the Amino Acid Sequence SEQ ID no. 29 or SEQ ID no. 32； and where And the Antibody or fragment thereof can bind specifically to human Ox40.Claim 42: Composition characterized in that it comprises an Antibody or fragment thereof of any of claims 1 to 41, and a Carrier.43: a polinucle u00f3tido claim, characterized in that it comprises a Nucleic Acid encoding the monoclonal antibody or fragment thereof, of any of claims 1 to 41, or sudunidad polypeptide Antibody or fragment thereof of any of claims 1 to 41.Claim 47: a method for producing an Antibody or fragment thereof, characterized in that it comprises cultivating the host Cell's claim 46 under conditions where the Antibody or fragment thereof is encoded by the polinucle u00f3tido, and recover the Antibodies Or fragment thereof.Claim 59: a method for treating cancer in a subject, characterized in that it comprises administering to a subject in need of treatment an effective amount of an Antibody or fragment thereof of any of claims 1 to 41 or 42, the composition of the claim.Reivindicación 1: Un anticuerpo o fragmento de unión a antígeno del mismo caracterizado porque comprende una región variable de cadena pesada (VH) humanizada y una región de cadena liviana variable (VL) humanizada； en donde la VH comprende una secuencia de aminoácidos con la fórmula: HFW1-HCDR1-HFW2-HCDR2-HFW3-HCDR3-HFW4, en donde HFW1 es la SEQ ID Nº 6 o la SEQ ID Nº 7, HCDR1 es l
